Publications

Publications

Filter Results: (1,253) Arrow Down
Filter Results: (1,253) Arrow Down Arrow Up

Show Results For

Show Results For

← Page 23 of 1,253 Results →

    Joshua D. Margolis

    Joshua Margolis is James Dinan and Elizabeth Miller Professor of Business Administration and the Unit Head for the Organizational Behavior unit. He is also Faculty Chair of the Program for Leadership Development. His research and teaching revolve around leadership... View Details

    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

      Ranjay Gulati

      Ranjay Gulati is the Paul R. Lawrence MBA Class of 1942 Professor of Business Administration and the former Unit Head of the Organizational Behavior Unit at Harvard Business School. He is an expert on leadership, strategy, and organizational issues... View Details

      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
      • 20 Nov 2007
      • First Look

      First Look: November 20, 2007

      discipline to nationalized banks. Pharmaceutical Regulation in the United States and Europe Author:Arthur Daemmrich Periodical:Focus on Law Studies 23, no 1 (fall 2007): 8-11 Read the full paper:... View Details
      Keywords: Martha Lagace
      • January 2009
      • Case

      When Supply is of Public Interest: Roche & Tamiflu

      The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu. The Roche group is a 40 billion CHF company consisting of a pharmaceutical division and a diagnostic... View Details
      Keywords: Global Strategy; Health Pandemics; Distribution; Logistics; Production; Supply Chain Management; Performance Capacity; Pharmaceutical Industry
      Related
      • July 2023
      • Case

      HealthVerity: Real World Data and Evidence

      By: Satish Tadikonda
      Andrew Kress (CEO and founder) and his team had built a promising marketplace business at HealthVerity serving its core market in healthcare, with a focus on pharmaceutical R&D and services. Thus far, HealthVerity’s products had been unique to the pharma and pharma... View Details
      Keywords: Growth and Development Strategy; Market Entry and Exit; Product Marketing
      Related
      • December 2018
      • Case

      Corporate Transformation at Merck KGaA, Darmstadt, Germany

      By: Joseph B. Fuller, Amy C. Edmondson, Daniela Beyersdorfer and Tonia Labruyere
      When Stefan Oschmann became CEO and chairman of the executive board of Merck KGaA, Darmstadt, Germany, in 2016, the company had started its transformation from a mid-tier traditional German industry player to a global modern science and technology player. The... View Details
      Keywords: Corporate Governance With Family Ownership; Transformation; Change Management; Restructuring; Corporate Governance; Family Ownership
      Related

        Paul A. Gompers

        Paul Gompers, Professor of Business Administration at the Harvard Business School, specializes in research on financial issues related to start-up, high growth, and newly public companies. Professor Gompers has an appointment in both the View Details
        Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
        • Web

        Named Fellowship Funds - Alumni

        Lowell and was a scientist in the aerospace industry prior to attending HBS. Following a career as a pharmaceutical executive and management consultant, she founded Circle of Life Partners, a network of clinical leaders, professionals,... View Details
        • 16 May 2023
        • HBS Case

        How KKR Got More by Giving Ownership to the Factory Floor: ‘My Kids Are Going to College!’

        pharmaceuticals and technology. Rouen cautions that the model works best in fast-growing companies, where employees can receive a sizeable payout, and in situations where a sale in the not-too-distant future can translate into wealth.... View Details
        Keywords: by Avery Forman

          Malcolm P. Baker

          Malcolm Baker is the Robert G. Kirby Professor of Business Administration at the Harvard Business School, where he teaches the required course in finance and a short immersive program on investing in life sciences.

          His research is in the... View Details

          Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
          • 02 Aug 2011
          • First Look

          First Look: August 2

          pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks revealed its vulnerability to political risk. Following the advent of the Nazi regime in 1933, the largely Jewish owned and managed... View Details
          Keywords: Sean Silverthorne
          • 21 Feb 2018
          • Research & Ideas

          When a Competitor Abandons the Market, Should You Advance or Retreat?

          Terminations: Learning from Competitors’ R&D Failures, Krieger explores how pharmaceutical companies choose to react strategically when a competitor exits the market during the development stage. These companies may decide further... View Details
          Keywords: by Rachel Layne; Pharmaceutical; Pharmaceutical

            Robert S. Huckman

            Robert Huckman is the Albert J. Weatherhead III Professor of Business Administration at Harvard Business School, the Howard Cox Faculty Chair of the HBS Healthcare Initiative, and the Unit Head for View Details

            Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

              V. Kasturi Rangan

              Kash Rangan is the Malcolm P. McNair Professor of Marketing at the Harvard Business School. Formerly the chairman of the Marketing Department (1998-2002), he is now the co-chairman of the school's Social Enterprise Initiative. He has taught in a wide variety of MBA... View Details

              Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

                Debora L. Spar

                Debora Spar is the Jaime and Josefina Chua Tiampo Professor of Business Administration at Harvard Business School and Senior Associate Dean for Business and Global Society. Her current research focuses on issues of gender and technology, and the interplay between... View Details

                Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

                  Krishna G. Palepu

                  KRISHNA G. PALEPU is the Ross Graham Walker Professor of Business Administration, and has served previously as Senior Advisor to the President of Harvard University, and Senior Associate Dean... View Details

                  Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
                  • 31 Jan 2007
                  • Working Paper Summaries

                  Behavioral Decision Research, Legislation, and Society: Three Cases

                  Keywords: by Max H. Bazerman
                  • 28 Mar 2023
                  • Research & Ideas

                  The FDA’s Speedy Drug Approvals Are Safe: A Win-Win for Patients and Pharma Innovation

                  Wiener Professor of Public Policy and Director of Health Policy Research at the Harvard Kennedy School of Government. Jennifer Kao of the University of California, Los Angeles and the FDA’s Kathleen Miller are also coauthors. Speeding innovation without compromising... View Details
                  Keywords: by Kasandra Brabaw; Pharmaceutical

                    Rohit Deshpande

                    Rohit Deshpandé is a Baker Foundation Professor and Sebastian S. Kresge Professor of Marketing, Emeritus at Harvard Business School, where he has been teaching in the Advanced Management Program,... View Details

                    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
                    • 09 Feb 2024
                    • HBS Case

                    Slim Chance: Drugs Will Reshape the Weight Loss Industry, But Habit Change Might Be Elusive

                    Year after year, millions of people make a new year’s resolution to lose weight. But because success traditionally depends on making major lifestyle changes, like eating healthier and exercising more, many people fall short of their fitness goals. Yet in 2024, more... View Details
                    Keywords: by Lane Lambert; Pharmaceutical; Pharmaceutical